“…Survivin has emerged as an attractive therapeutic target and potentially important prognostic marker in many tumor types, including human gliomas (Ambrosini et al, 1997;Adida et al, 1998Adida et al, , 2000Kawasaki et al, 1998;Lu et al, 1998;Monzo et al, 1999;Asanuma et al, 2000;Islam et al, 2000;Olie et al, 2000;Tanaka et al, 2000;Grossman et al, 2001;Smith et al, 2001;Merlo, 2003). There have been four recent studies demonstrating that Survivin expression is associated with glioma progression from low-to high grade (Tan et al, 1993;Chakravarti et al, 2002;Sasaki et al, 2002;Kajiwara et al, 2003;Katoh et al, 2003).…”